High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid
- 7 October 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 68 (1), 239-245
- https://doi.org/10.1007/s00280-010-1474-y
Abstract
Purpose Sorafenib is recommended for therapy of advanced hepatocellular carcinoma and renal cell carcinoma. Preclinical data indicate a relation between dose and antitumor efficacy. In clinical trials, adverse events improve after dose reduction suggesting a dose-dependent toxicity. Given dose has a direct impact on the drug serum concentration, but the latter also can be influenced by multiple factors, including interaction and metabolisation. To enable the investigation of concentration-related effects, an easy and sensitive assay for sorafenib drug monitoring is essential. Methods A high-performance liquid chromatography (HPLC) analysis involving an extraction with diethyl ether followed by separation on a Pinnacle™ DB C18 column and quantitation by UV absorbance at 260 nm was established. Sorafenib concentrations in samples of serum and peritoneal fluid have been determined. Results The assay was validated for serum samples and is linear over the concentration range of 100–5,000 ng/ml with a determination coefficient of >0.999. The limit of detection is 0.25 ng/ml. The intra- and inter-day coefficients of variation were below 3.03%. Sorafenib recovery in spiked probes of peritoneal fluid was above 85%. Sorafenib concentrations in 44 serum samples and 14 probes of peritoneal fluid have been determined with a mean of 3,328 and 1,380 ng/ml, respectively (standard deviation 2,267 and 659 ng/ml). Conclusions A sensitive and selective HPLC method for the determination of sorafenib in human serum was developed and also verified for peritoneal fluid. This method provides a useful tool for pharmacokinetic investigations as well as for therapeutic drug monitoring of sorafenib.Keywords
This publication has 24 references indexed in Scilit:
- Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and TherapyAnnual Review of Medicine, 2010
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practiceJournal of Pharmaceutical and Biomedical Analysis, 2009
- SorafenibDrugs, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2008
- Phase I study of sorafenib in Japanese patients with hepatocellular carcinomaCancer Science, 2007
- Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenibEuropean Journal of Cancer, 2007
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?European Journal of Cancer, 2006